A pilot, randomized, placebo-controlled trial of rimegepant on visceral sensation and symptoms in nonconstipation IBS pain

American Journal of Physiology-Gastrointestinal and Liver Physiology 2026

View at publisher
Authors: Houssam Halawi, Ayah Matar, Iris Wang, Kara J. Jencks, Irene A. Busciglio, Deborah J. Eckert, William S. Harmsen, Michael Camilleri
DOI: 10.1152/ajpgi.00394.2025
Cited by: 1
References: 36

Abstract

This pilot, randomized, double-blind trial in a relatively small sample of patients with IBS-related pain shows rimegepant significantly reduced sensations of gas, urgency, and pain during rectal distention and decreased rectal compliance. Decrease in compliance implies that changes in physical properties or distensibility of rectum did not contribute to alterations in rectal sensation. Same dose of rimegepant did not significantly impact daily abdominal pain, BM frequency, or colonic transit. There were no serious adverse events.

Fields of Study & Subjects

Gastrointestinal motility and disorders Enhanced Recovery After Surgery Congenital gastrointestinal and neural anomalies

Publication details

Journal / source
American Journal of Physiology-Gastrointestinal and Liver Physiology
Publisher
American Physiological Society
Volume
330
Issue
4
Pages
G369–G380
Publication date
4 February 2026
Language
EN